Showing results (71-80 of 176) with videos related to
Sort By:
Pageof 18
BJU International|July 13, 2020
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)Alejo Rodriguez-Vida, Aristotelis Bamias, Emilio Esteban, et al.Oncology|October 17, 2002
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot studyEmiliano Calvo, Javier Cortés, María González-Cao, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I studyRebecca Kristeleit, Victor Moreno, Valentina Boni, et al.British Journal of Cancer|February 16, 2023
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumoursJayesh Desai, Peter Fong, Victor Moreno, et al.The Oncologist|June 2, 2018
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyEmiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.Journal for Immunotherapy of Cancer|January 30, 2019
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, et al.European Urology|February 3, 2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 TrialCamillo Porta, Emiliano Calvo, Miguel A Climent, et al.Molecular Cancer Therapeutics|July 7, 2023
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation StudyFunda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.Pageof 18